Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT03808922 · View on ClinicalTrials.gov ↗
Study Summary
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DAS181
- DRUG DAS181 COVID-19
- DRUG DAS181 OL
Study Locations (20)
California
- City of Hope cancer Center — Duarte
- UCLA — Los Angeles
- University of California Davis Health System — Sacramento
- University of California San Diego Medical Center — San Diego
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago
- University of Chicago — Chicago
- Loyola University Medical Center — Maywood
Florida
- Sylvester Comprehensive Cancer Center, University of Miami Health System — Miami
- Houston Methodist Hospital — Tampa
Maryland
- University of Maryland — Baltimore
- The Johns Hopkins Hospital — Baltimore
Massachusetts
- Brigham and Women's Hospital — Boston
- Beth Israel Deaconess Medical Center — Boston
Colorado
- Children's Hospital Colorado — Aurora
Iowa
- University of Iowa Health Care — Iowa City
Kansas
- University of Kansas Medical Center — Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03808922
The ClinicalTrials.gov registry entry for NCT03808922 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ansun Biopharma, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 4 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03808922 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Illinois, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03808922 about?
NCT03808922 is a clinical study titled "Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study". This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
What is the current status of trial NCT03808922?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2019-05-23. Estimated completion is 2025-08-31.
What conditions does trial NCT03808922 study?
This clinical trial studies the following conditions: COVID-19, Lower Respiratory Tract Infection, Immunocompromised, Parainfluenza. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03808922?
The interventions under investigation include: Placebo (DRUG), DAS181 (DRUG), DAS181 COVID-19 (DRUG), DAS181 OL (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03808922?
This trial is sponsored by Ansun Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03808922 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.